Patient-reported treatment satisfaction measures for long-term anticoagulant therapy.

abstract：:The Institute for Quality and Efficiency in Health Care in Germany makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effects in each therapeutic area. The analysis requires, when applicable, calculation of savings from avoided clinical events and increased f...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gandjour A,Gafni A

更新日期：2011-08-01 00:00:00

abstract：:The second Medicines Utilization Research in Africa (MURIA) group workshop and symposium again brought researchers together from across Africa to improve their knowledge of drug utilization (DU) methodologies and exchange ideas to further progress DU research in Africa. This built on extensive activities from the firs...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Massele A,Burger J,Kalemeera F,Jande M,Didimalang T,Kalungia AC,Matshotyana K,Law M,Malone B,Ogunleye O,Oluka M,Paramadhas BD,Rwegerera G,Zinyowera S,Godman B

更新日期：2017-04-01 00:00:00

abstract：:Prostate cancer is the most common non-skin cancer in American men, and prostate-specific antigen (PSA) testing is its common screening procedure. In May 2012, the US Preventive Services Task Force recommended against PSA-based screening. These recommendations contradict the current recommendations of other organizati...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Garg V,Gu NY,Borrego ME,Raisch DW

更新日期：2013-06-01 00:00:00

abstract：:A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Shepherd J,Jones J

更新日期：2007-12-01 00:00:00

abstract：INTRODUCTION:During the past few years, medical-economic evaluation of lung cancers (LCs) has become unavoidable. Total management costs have been rising constantly, with values almost doubling every 10 years. The financial impact will be even greater with the new molecules now marketed. The methodology for these studi...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Vergnenègre A,Chouaïd C

更新日期：2018-10-01 00:00:00

abstract：:Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no internationa...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hirsch EB,Tam VH

更新日期：2010-08-01 00:00:00

abstract：OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wang X,Chen H,Ej E,Wu J,Serna O,Paranjpe R,Abughosh S

更新日期：2020-08-01 00:00:00

abstract：:Social Security Disability Insurance provides cash benefits to disabled workers and certain others under the age of 65 years. These individuals become eligible for Medicare 24 months after Social Security Disability Insurance cash benefits start. In 2001, 13.9% of Medicare's approximately 40 million beneficiaries were...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Iezzoni LI

更新日期：2006-06-01 00:00:00

abstract：:Osteoarthritis is the single most important cause of disability and limitation of activity of elderly people in the UK. Although joint replacement is now commonplace for hips and increasingly so for knees, pharmacological management continues to be important. In this context, it is necessary to identify valid and acce...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Walters SJ,Lloyd-Jones M

更新日期：2002-08-01 00:00:00

abstract：:It is well accepted that psoriasis has a profound impact on the life of the patient. Moderate-to-severe psoriasis frequently requires phototherapy or aggressive systemic treatment; unfortunately these treatments have major limitations. New biologic treatments are now available that offer distinct safety advantages and...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Feldman SR,Pearce DJ

更新日期：2004-10-01 00:00:00

abstract：:Adenosine and dipyridamole are coronary vasodilators used in nuclear imaging. The acquisition cost of adenosine is four to ten times higher than dipyridamole. Data suggest comparable sensitivity, although specificity may be lower with dipyridamole. While side effect profiles are similar, fewer patients who receive ade...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Reddy P

更新日期：2002-12-01 00:00:00

abstract：:There have been great technological advances in the use of antiretroviral therapies to slow down disease progression in HIV/AIDS. Combinations of therapeutics and the use of several diagnostic methods have resulted in both declines in mortality and the occurrence of opportunistic infections. The higher costs of these ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bos JM,Berg LT,Postma MJ

更新日期：2001-10-01 00:00:00

abstract：:Fondaparinux sodium is the first in a new class of anticoagulants that selectively inhibits Factor Xa. It produces a predictable pharmacologic response, obviating the need for coagulation monitoring. Additionally, this agent does not bind to platelet Factor 4, thereby reducing the risk of thrombocytopenia. Clinical tr...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wade WE,Spruill WJ

更新日期：2007-06-01 00:00:00

abstract：:Growing understanding of the mechanisms and epidemiology of neonatal herpes simplex virus acquisition allows for the development of a new management of the pregnant patient, one that will reduce the risk of transmitting herpes to the newborn. Maternal herpes simplex virus infection, especially acquired during pregnanc...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Baker DA

更新日期：2005-12-01 00:00:00

abstract：:This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

更新日期：2014-10-01 00:00:00

abstract：BACKGROUND:Although Health Technology Assessment (HTA) is increasingly used to support evidence-based decision-making in health care, several barriers and facilitators for the use of HTA have been identified. This best-worst scaling (BWS) study aims to assess the relative importance of selected barriers and facilitator...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Feig C,Cheung KL,Hiligsmann M,Evers SMAA,Simon J,Mayer S

更新日期：2018-04-01 00:00:00

abstract：:The Resonance metallic stent is a new wire-based ureteral stent that was initially developed for patients with malignant ureteral obstruction. Potential advantages over traditional stents include resistance to encrustation and to external compression, allowing for increased dwell times and the maintenance of upper tra...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Polcari AJ,Hugen CM,López-Huertas HL,Turk TM

更新日期：2010-02-01 00:00:00

abstract：:Quality of life has become an important end point in clinical trials and academic studies. The questionnaires developed by the European Organisation for Research and Treatment of Cancer Quality of Life Group are widely used to measure quality of life in cancer patients. The expanding geographical coverage of current s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kuliś D,Arnott M,Greimel ER,Bottomley A,Koller M,European Organisation for Research and Treatment of Cancer Quality of Life Group.

更新日期：2011-06-01 00:00:00

abstract：:At least 14% of cancer patients live with minor children. Being a parent with cancer has far-reaching consequences for individual treatment decision-making and quality of life in patients and their families. Even though the majority of children and adolescents do not show clinically relevant symptoms of psychopatholog...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Krauel K,Simon A,Krause-Hebecker N,Czimbalmos A,Bottomley A,Flechtner H

更新日期：2012-12-01 00:00:00

abstract：INTRODUCTION:Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Inotai A,Ágh T,Karpenko AW,Zemplényi A,Kaló Z

更新日期：2019-04-01 00:00:00

abstract：:Nursing homes are facing increased environmental pressures to improve quality of care. However, this increased emphasis on quality comes at a time when nursing homes are facing revenue constraints as a result of the repeal of the Boren amendment, increased reimbursement based on prospective payment systems and widespr...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Weech-Maldonado R,Mor V,Oluwole A

更新日期：2004-02-01 00:00:00

abstract：:Evaluation of: Levin LA, Wallentin L, Bernfort L et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes results from the PLATO trial. Value Health 16(4), 574-580 (2013). Antiplatelet therapy is considered essential treatment for acute coronary syndromes with or...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： De Franco AC,Oldridge N

更新日期：2014-02-01 00:00:00

abstract：AIM:To review and compare methods for indirect comparison of aflibercept and ranibizumab in patients with diabetic macular edema. METHODS:Post-stratification, inverse probability weighting based on simulated data, weight optimization, and regression model techniques were used to compare pooled individual patient-level...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Regnier SA,Alsop J,Wright J,Nixon R,Staines H,Fajnkuchen F

更新日期：2016-12-01 00:00:00

abstract：:The 15th International Symposium for Health Information Management Research (ISHIMR) was organized jointly by University Hospital Zurich (Switzerland), the University of St Gallen (St Gallen, Switzerland) and the University of Sheffield (Sheffield, UK). Participants included researchers, healthcare professionals, heal...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bath PA,Sen BA,Raptis DA,Mettler T

更新日期：2012-02-01 00:00:00

abstract：:Differential item functioning (DIF) analyses are used to determine whether certain groups respond differently to a particular item of a test or questionnaire; however, these do not explain the reasons for observed response differences. Many studies have used external reviews of items, sometimes using blinded reviewers...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Scott NW,Fayers PM,Aaronson NK,Bottomley A,de Graeff A,Groenvold M,Gundy C,Koller M,Petersen MA,Sprangers MA,EORTC Quality of Life Group.,Quality of Life Cross-Cultural Meta-Analysis Group.

更新日期：2010-06-01 00:00:00

abstract：:Interest is rising in measuring subjective health outcomes, such as treatment outcomes that are not directly quantifiable (functional disability, symptoms, complaints, side effects and health-related quality of life). Health economists in particular have applied probabilistic choice models in the area of health evalua...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Arons AM,Krabbe PF

更新日期：2013-02-01 00:00:00

abstract：BACKGROUND:Chronic pancreatitis (CP) is a leading cause of hospitalization among gastrointestinal diseases resulting in considerable financial burden to patients. However the direct costs for nonsurgical management in CP remains unexplored. METHODS:A cross sectional study was carried out (2011-14) in the Department of...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kamat N,Pai G,Mallayasamy SR,Kamath A,S R

更新日期：2018-06-01 00:00:00

abstract：:This review considers some of the broad principles that concern quality of life assessment. These are discussed in relation to health-related quality of life (HRQOL) and the measurement of subjective well-being. It is argued that there are serious logical and methodological issues concerning HRQOL measurement, to the ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Cummins RA,Lau AL,Stokes M

更新日期：2004-08-01 00:00:00

abstract：:This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Lo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Ivanovic N,Beinema M,Brouwers JR,Naunton M,Postma MJ

更新日期：2007-02-01 00:00:00

abstract：:The goal of asthma management during pregnancy is to keep the mother symptom free and to prevent complications in the fetus. Asthma is a common chronic condition in pregnancy that, if inadequately treated, has the potential to cause adverse effects for both mother and fetus. Aggressive treatment during pregnancy can d...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Streck MR,Blaiss MS

更新日期：2006-02-01 00:00:00